Therapeutics News and Research

RSS

Ikaria Holdings acquires NDA and IND application for LUCASSIN drug

Ikaria Holdings, Inc. announced today that it has acquired the New Drug Application (NDA) and the Investigational New Drug (IND) application to LUCASSIN® (terlipressin for injection) from Orphan Therapeutics, assuming all future development and ownership of the drug in North America and Australia.

31 Mar 2010

Ascent Therapeutics is now Anchor Therapeutics

Ascent Therapeutics announced today that it has adopted a new name — Anchor Therapeutics. Anchor Therapeutics reflects the Company's core technology and its commitment to building solid, dependable value for patients, partners and investors via its proprietary platform technology.

30 Mar 2010

StockPreacher.com releases investment report on MDRNA

StockPreacher.com announces an investment report featuring drug developer MDRNA Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

30 Mar 2010

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

Silence Therapeutics plc today announced that the company and Dainippon Sumitomo Pharma Co., Ltd. have agreed to an expansion of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in August 2009, the companies are leveraging Silence's proprietary siRNA molecules and multiple lipid delivery and targeting technologies to demonstrate functional delivery of RNA interference (RNAi) therapeutics to specific disease targets in the body.

30 Mar 2010

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.

30 Mar 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.

30 Mar 2010

Tomato genes could be used as future treatment in gene therapy: Study

Tomato genes could be used as a future treatment in gene therapy, according to new research results from Lund University.

30 Mar 2010

Potential new target for treating HCV infection

A team of scientists including University of Utah researchers has discovered that binding of a potent inhibitor of the hepatitis C virus to the genetic material of the virus causes a major conformational change that may adversely affect the ability of the virus to replicate.

30 Mar 2010

DIATHERIX GI test panel can detect nine types of GI infections

DIATHERIX Laboratories adds a gastrointestinal panel to its lineup of highly sensitive, rapid response diagnostic tests. In a single result, the DIATHERIX GI panel can detect and differentiate nine types of GI infections so physicians can quickly identify patients who have severe, life-threatening infections.

30 Mar 2010

Trius Therapeutics' Phase 1 trial establishes safety and tolerability of IV torezolid phosphate for MRSA

Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).

30 Mar 2010

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Alcon, the world's leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc.

30 Mar 2010

Unrestricted availability of food can trigger overconsumption and obesity

Some of the same brain mechanisms that fuel drug addiction in humans accompany the emergence of compulsive eating behaviors and the development of obesity in animals, according to research funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health.

29 Mar 2010

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.

29 Mar 2010

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.

29 Mar 2010

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.

29 Mar 2010

Redpoint Bio announces revenue of $1.9M for full-year 2009

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the quarter and year ended December 31, 2009.

29 Mar 2010

ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009

ARYx Therapeutics, Inc. today reported results of operations and provided an update on its products for the fourth quarter and year ended December 31, 2009.

29 Mar 2010

Addiction to high calorie fat rich food: likened to cocaine and heroin addiction

In a new research our worst fears are confirmed – fatty, fried and fattening foods are addictive. The addiction with these delicious ‘yummies’ may be as potent as that with cocaine or heroin. The study was conducted on experimental animals, rats in this case. When fed with fatty foods in great quantities these rats showed a compulsive need to eat.

29 Mar 2010

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.

29 Mar 2010

Therapeutics News and Research

Ikaria Holdings acquires NDA and IND application for LUCASSIN drug

Ascent Therapeutics is now Anchor Therapeutics

StockPreacher.com releases investment report on MDRNA

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

Tomato genes could be used as future treatment in gene therapy: Study

Potential new target for treating HCV infection

DIATHERIX GI test panel can detect nine types of GI infections

Trius Therapeutics' Phase 1 trial establishes safety and tolerability of IV torezolid phosphate for MRSA

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Unrestricted availability of food can trigger overconsumption and obesity

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Redpoint Bio announces revenue of $1.9M for full-year 2009

ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009

Addiction to high calorie fat rich food: likened to cocaine and heroin addiction

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

Next-generation therapeutics eBook eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News